[8-K] ANGIODYNAMICS INC Reports Material Event

AngioDynamics, Inc. reported stockholder voting results.

Rhea-AI Filing Summary

AngioDynamics, Inc. reported stockholder voting results. Shareholders elected two directors: James C. Clemmer received 29,634,152 votes for and 800,454 withheld, with 5,462,943 broker non-votes; Michael E. Tarnoff, MD received 29,245,896 votes for and 1,188,710 withheld, with 5,462,943 broker non-votes.

Stockholders also approved two additional items. One item received 35,727,186 votes for, 156,899 against, and 13,464 abstentions; there were no broker non-votes for this item. Another item received 28,357,782 votes for, 2,057,982 against, 18,842 abstentions, and 5,462,943 broker non-votes.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which directors were elected to AngioDynamics (ANGO)'s board?

Shareholders elected James C. Clemmer and Michael E. Tarnoff, MD.

How many votes did each ANGO director nominee receive?

Clemmer: 29,634,152 for, 800,454 withheld; Tarnoff: 29,245,896 for, 1,188,710 withheld. Each had 5,462,943 broker non-votes.

Did ANGO shareholders approve other proposals?

Yes. One item passed with 35,727,186 for, 156,899 against, 13,464 abstentions (no broker non-votes). Another passed with 28,357,782 for, 2,057,982 against, 18,842 abstentions, and 5,462,943 broker non-votes.

Were there broker non-votes on ANGO proposals?

For the 35,727,186-for item, there were no broker non-votes. The other item had 5,462,943 broker non-votes.

What is AngioDynamics’ trading symbol and exchange?

Common stock trades as ANGO on the NASDAQ Global Select Market.

What type of filing disclosed the voting results for ANGO?

An 8-K disclosed the shareholder voting results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 07:01 AM Learn about SEC filing dates

false000127518700012751872025-11-102025-11-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 10, 2025

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	000-50761	11-3146460
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

14 Plaza Drive, Latham, New York		12110
(Address of Principal Executive Offices)		(Zip Code)

(518) 795-1400

(Registrant’s telephone number, including area code)

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		ANGO		NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 –
Submission of Matters to a Vote of Security Holders.

(a) The Annual Meeting of Shareholders of AngioDynamics, Inc. (“AngioDynamics”) was held on November 10, 2025.

(b) Shareholders of AngioDynamics voted on the matters set forth below.

1. The nominees for election to the Board of Directors were elected, each as a Class I director to serve until the 2028 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes:

Nominee	Votes For	Withheld	Broker Non-Votes
James C. Clemmer	29,634,152	800,454	5,462,943
Michael E. Tarnoff, MD	29,245,896	1,188,710	5,462,943

2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics’ independent registered public accounting firm for the fiscal year ending May 31, 2026 was approved based upon the following votes:

Votes for approval	35,727,186
Votes against	156,899
Abstentions	13,464

There were no broker non-votes for this item.

3. The proposal to approve, on an advisory basis, AngioDynamics’ executive compensation of its named executive officers was approved based upon the following votes:

Votes for approval	28,357,782
Votes against	2,057,982
Abstentions	18,842
Broker non-votes	5,462,943

(c) Not applicable.

(d) Not applicable.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANGIODYNAMICS, INC.
	(Registrant)
Date:  November 12, 2025	By:	/s/ Lawrence T. Weiss
		Name:  Lawrence T. Weiss
		Title:    Senior Vice President, Chief Legal Officer and Corporate Secretary